MS
IMDX

Maven Securities’s Insight Molecular Diagnostics IMDX Stock Holding History

Maven Securities’s Portfolio IMDX Stock Details IMDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-23,834
Closed -$2.73M – 1210
2021
Q2 		$2.73M Buy
23,834
+14,167
+147% +$1.38M 0.11% 168
2021
Q1 		$1.01M Buy
+9,667
New +$918K 0.05% 410
2019
Q3 		– Sell
-10,776
Closed -$550K – 218
2019
Q2 		$550K Buy
+10,776
New +$896K 0.37% 53

Other funds holding IMDX

BC
Broadwood Capital New York $1.42B AUM 34.72% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DC
Defender Capital Charlotte, North Carolina $308M AUM 4.52% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Maven Securities's IMDX Position: Q3 2021 in Review

Maven Securities sold out of Insight Molecular Diagnostics (IMDX) in Q3 2021, closing a stake of 23,834 shares — an estimated $2.73M sold.

Maven Securities first reported a position in IMDX in Q2 2019 and held it in 3 quarters. The position peaked at $2.73M in Q2 2021. 95 funds tracked by Wall St. Rank hold IMDX as of Q3 2021.

  • Maven Securities reported no remaining Insight Molecular Diagnostics position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 23,834 Insight Molecular Diagnostics shares in Q3 2021, an estimated $2.73M.
  • Maven Securities first reported a position in Insight Molecular Diagnostics in Q2 2019 and held it in 3 quarters.
  • Maven Securities's Insight Molecular Diagnostics position peaked at $2.73M in Q2 2021.
  • 95 funds tracked by Wall St. Rank held Insight Molecular Diagnostics as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.